Top 10 Income Companies To Buy Right Now

UBS said Tuesday that its first-quarter profits improved about 7%. It had net income of 1.05 billion Swiss francs, or about $1.2 billion, versus 988 million francs a year ago, beating estimates.

The company’s revenue in Q1 was about $7.23 billion, a drop of roughly 7% from last year, though it had net-new-money inflows of 12.8 billion Swiss francs into its wealth management units.

“I’m pleased with the first quarter as we demonstrated sustainable profitability across all business divisions and regions,” said Group CEO Sergio Ermotti, in a press release. “Dedicated and disciplined execution of our strategy for the benefit of clients and shareholders remains our top priority.”

Wealth Management Americas had a pretax profit of $272 million, up 7% from the prior period and 30% year over year; after adjustments, the pretax profit for Q1’14 was $284 million; expenses declined roughly 1% year over year.

Revenue for the U.S.-based unit was about 1.66 billion Swiss francs, down slightly from 1.67 billion a year ago.

Top Warren Buffett Companies To Invest In Right Now: Continental Resources Inc. (CLR)

Continental Resources, Inc. engages in the exploration, development, and production of crude oil and natural gas primarily in the north, south, and east regions of the United States. The company primarily sells its oil and natural gas production to end users, as well as to midstream marketing companies or oil refining companies at the lease. As of December 31, 2011, its estimated proved reserves were 508.4 million barrels of crude oil equivalent, with estimated proved developed reserves of 205.2 million barrels of crude oil equivalent. The company had interests in 3,255 wells and served as the operator of 2,082 of these wells. Continental Resources, Inc. was founded in 1967 and is headquartered in Enid, Oklahoma.

Advisors' Opinion:

• [By Tyler Crowe]

  There are not many companies that have�benefited�more from the North American oil and gas boom than Continental Resources (NYSE: CLR  ) . Not only has the company gone on a recent tear of beating analyst expectations, but production growth has been soaring for this Bakken-heavy producer.

• [By Matt DiLallo]

  Bakken producers like Continental Resources (NYSE: CLR  ) seem to have a sweet spot for this age-old mode of transportation. The company and its peers had been producing more oil than the current pipeline infrastructure could handle. That created a huge differential between the price of Bakken crude and that of U.S. benchmark West Texas Intermediate. However, thanks to the rails, that differential has come down significantly.

• [By Matt DiLallo]

  America began turning around its reserve picture about five years ago. This is when energy companies like EOG Resources (NYSE: EOG  ) and Continental Resources (NYSE: CLR  ) discovered that we actually could economically produce oil out of the Eagle Ford and Bakken Shale plays. The ensuing boom now has America's proved oil reserves at the highest level since 1976.

Top 10 Income Companies To Buy Right Now: SPDR DB International Government Inflation-Protected Bond ETF (WIP)

SPDR DB International Government Inflation-Protected Bond ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the DB Global Government ex-US Inflation-Linked Bond Capped Index (the Index). The Index measures the performance of the inflation-linked government bond markets of developed and emerging market countries outside of the United States. Inflation protected public obligations of the inflation-linked government bond markets of developed and emerging market countries, commonly known in the United States as treasury inflation-protected securities (TIPS), are securities issued by such governments that are designed to provide inflation protection to investors. The Fund uses a passive management strategy to track the Index. The Fund�� investment advisor is SSgA Funds Management, Inc. Advisors' Opinion:

• [By Richard Stavros]

  With respect to inflation protected bonds, though TIPS should be a part of every portfolio. However, we believe the SPDR DB International Government Inflation-Protected Bond (WIP) offers greater protection than TIPS.

Top 10 Income Companies To Buy Right Now: Essex Rental Corp (ESSX)

Essex Rental Corp., incorporated on August 21, 2006, through its subsidiaries, is engaged in providing of lifting equipment (including lattice-boom crawler cranes, truck cranes and rough terrain cranes, tower cranes, and other lifting equipment) used in an array of construction projects. In addition, it provides product support including installation, maintenance, repair, and parts and services for its equipment provided to customers and customer owned equipment. It operates in three segments: equipment rentals, equipment distribution, and parts and service. Its subsidiaries wholly owned subsidiaries include Essex Holdings, LLC (Holdings), Essex Crane Rental Corp. (Essex Crane), Essex Finance Corp. (Essex Finance), CC Acquisition Holding Corp. (CC Acquisition), Coast Crane Company, (Coast Crane) and Coast Crane Ltd. (Coast Crane Ltd.).

The Company supply a variety of lifting solutions for construction projects related to power generation, petro-chemical, refineries, water treatment and purification, bridges, highways, hospitals, shipbuilding, offshore oil fabrication and industrial plants, and commercial and residential construction. It rent its equipment bare, meaning without supplying an operator and, in exchange for a fee, make arrangements for the transportation and delivery of equipment.

Essex Crane is a provider of lattice-boom crawler crane and attachment rental services and possesses fleets of such equipment in the United States. As of December 31, 2011, Essex Crane�� fleet size stands at more than 350 lattice-boom crawler cranes and various types of attachments, which are made available to clients depending on their lifting requirements, such as weight, pick and carry aspects, reach and angle of reach.

Coast Crane is a provider for lifting solutions throughout Western North America, Alaska, Hawaii, Guam and the South Pacific. Through Coast Crane, it provides both used and new towers cranes, boom trucks, rough terrain cranes and other lifting equipment ! to customers in the infrastructure, energy, crane rigger/operator, and municipal, commercial and industrial construction sectors. Coast Crane�� operations are headquartered in Seattle, Washington and its products are rented and sold through a regional network including 11 branch locations. In addition to providing crane rental services, Coast Crane is a crane distributor of self-erecting tower cranes, rough terrain cranes, boom trucks and all terrain cranes in its West Coast territories.

Equipment Rental

The Company offer for rent crawler cranes and attachments, rough terrain cranes, boom trucks, tower cranes, and other construction related rental equipment. It also offer transportation, rigging and repair and maintenance services while equipment is on rent. It rent its fleet of over 1,000 cranes and attachments and other lifting equipment to a variety of engineering and construction customers under contracts, most of which have rental periods of between 4 and 18 months. The contracts typically provide for an agreed rental rate and a specified rental period. Transportation services revenue is derived from the management of the logistics process by which its rental equipment is transported to and from customers��construction sites, including the contracting of third party trucking for such transportation.

Equipment Distribution

The Company offers a variety of construction equipment products for sale, including tower cranes, boom trucks, rough terrain cranes and other lifting equipment used in the construction industry. The revenue from retail equipment sales is primarily driven by the level of construction activity in a particular geographic region.

Parts and Service

The Company is a parts distributor for various lifting equipment manufacturers and routinely sells parts to its customers in the construction industry. It also provides repairs and maintenance services for customers that own their own equipment and request its ! services ! at one of its service center locations. Its customers for these ancillary services are its rental customers, customers that own their own equipment and those who purchase new and used equipment from it.

The Company competes with ALL Erection & Crane Rental, Bigge Crane and Rigging, Co., Lampson International, Maxim Crane Works, M.D., Morrow Equipment Rental, Western Pacific Crane and Equipment and AmQuip Crane Corp.

Advisors' Opinion:

• [By Peter Graham]

  The Q2 2014 earnings report for equipment rental stock United Rentals, Inc (NYSE: URI), a peer or competitor of Essex Rental Corp (NASDAQ: ESSX) and H&E Equipment Services, Inc (NASDAQ: HEES), is scheduled for after the market closes on Wednesday. Aside from the United Rentals earnings report, it should be said that the Essex Rental Corp reported Q4 2013 earnings on May 7th while the estimated release date for the H&E Equipment Services, Inc Q2 2014 earnings report is August 4th. However, United Rentals��shares rose after its last earnings report plus analysts have issued bullish research notes since then.

• [By Monica Gerson]

  Essex Rental (NASDAQ: ESSX) is projected to post a Q4 loss at $0.10 per share on revenue of $22.55 million.

  Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top 10 Income Companies To Buy Right Now: Atossa Genetics Inc (ATOS)

Atossa Genetics Inc., incorporated on April 30, 2009, is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions. The Company�� diagnostic tests consist of medical devices cleared by the Food and Drug Administration (FDA), which can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. During the fiscal year ended September 30, 2012, the tests that the Company offered and that are in development consist of ForeCYTE, ArgusCYTE, FullCYTE and NextCYTE. In September 2012, the Company acquired all of the assets of Acueity.

The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 73. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. MASCT, Oxy-MASCT, and its name and logo are the trademarks. ForeCYTE, FullCYTE, NextCYTE, and ArgusCYTE are its service marks.

Advisors' Opinion:

• [By Roberto Pedone]

  One stock that's starting to push within range of triggering a big breakout trade is Apple (ATOS), which is involved in the prevention of breast cancer through the commercialization of diagnostic medical devices and laboratory developed tests that can detect precursors to breast cancer. This stock is off to a decent start in 2013, with shares up 24%.

  If you take a look at the chart for Atossa Genetics, you'll notice that this stock has been starting to uptrend over the last month, with shares moving higher from its low of $4.22 to its recent high of $5.08 a share. During that uptrend, shares of ATOS have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ATOS within range of triggering a big breakout trade above a key downtrend line that dates back to May.

  Traders should now look for long-biased trades in ATOS if it manages to break out above some key overhead resistance levels at $5.08 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 74,575 shares. If that breakout hits soon, then ATOS will set up to re-test or possibly take out its next major overhead resistance levels at $5.60 to $6.23 a share. Any high-volume move above $6.23 will then put $7 to $7.50 into range for shares of ATOS.

  Traders can look to buy ATOS off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.42 or at $4.22 a share. One could also buy ATOS off strength once it takes out $5.08 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Rebecca McClay]

  Atossa Genetics Inc. (Nasdaq: ATOS) shares are up about 6% in midday trading due to a cancer breakthrough it plans to showcase this weekend...

  Atossa will exhibit its ForeCYTE Breast Health Test at the 2013 Breast Cancer Symposium in San Francisco, CA, which starts Saturday.

• [By Bryan Murphy]

  You know, it's fun to be right about a particular stock, but at the same time, it's miserable if you didn't have the guts to actually act on the idea. That's my tale of woe with Atossa Genetics Inc. (NASDAQ:ATOS). On Monday of this week I was singing its praises, explaining how the chart suggested ATOS was on the verge of a breakout. But, I also suggested waiting for shares to take that one final confirming step.... a move above the 100-day moving average line. Now I wish I hadn't been so picky.

Top 10 Income Companies To Buy Right Now: C.R. Bard Inc. (BCR)

C. R. Bard, Inc., together with its subsidiaries, engages in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular, urology, oncology, and surgical specialty products. The company?s vascular products include percutaneous transluminal angioplasty catheters, chronic total occlusions catheters, guidewires, introducers, and accessories; peripheral vascular stents and stent grafts, vena cava filters, and biopsy devices; electrophysiology products, such as electrophysiology laboratory systems and diagnostic, therapeutic, and temporary pacing electrode catheters; and fabrics, meshes, and implantable vascular grafts. Its urology products comprise infection control Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; natural and synthetic devices to treat pelvic floor and vaginal prolapse; brachyt herapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for ureteroscopic procedures and stone removal; and catheter stabilization devices. The company?s oncology products consist of specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation systems for hernia and other soft tissue repairs; irrigation devices for orthopedic, laparoscopic, and gynecological procedures; and products for topical hemostasis. C. R. Bard sells its products directly and through distributors to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. The company was founded in 1907 and is based in Murray Hill, New Jersey.

Advisors' Opinion:

• [By ovenerio]

  In the medical devices business (83% of FY 13 sales), the company competes with good health care companies such as Johnson & Johnson (JNJ), C.R. Bard (BCR) and ConMed (CNMD).

• [By Jonas Elmerraji]

  At least mid-cap medical device maker C.R. Bard (BCR) has been able to keep pace with the S&P this year. Bard makes medical consumables -- one-time-use products designed for an array of medical, surgical, and diagnostic uses. The firm's offerings include everything from biopsy needles and catheters to ultrasound systems.

  It's the focus on the consumable side of the business, though, that's been fuelling Bard's top line in 2013. All together, consumables make up around 90 cents out of every dollar the firm earns -- and they come with deep margins and recurring orders as well. A rising tide should help to lift all ships in the medical device market; whatever you think about programs like Obamacare, the net result is more patients and higher rates of medical consumables used.

  One of Bard's biggest selling points is preventative -- the firm's top-selling catheters, for instance, help to reduce the likelihood of patient infection, a complication that comes with astronomical costs for hospitals. That proprietary advantage gives Bard an edge in a device that otherwise appears pretty low-moat.

  In my view, Bard is a good example of a strong middle-of-the-road health care name. It's certainly not the most exciting company in the sector (far from it), but it's worth owning for investors looking for health exposure in 2013. Institutions picked up 2.26 million shares of Bard, boosting their stakes by more than 20% in the last quarter.

Top 10 Income Companies To Buy Right Now: Medley Capital Corporation (MCC)

Medley Capital Corporation is a business development company. The fund seeks to invest in privately negotiated debt and equity securities of small and middle market companies. It targets private debt transactions ranging in size from $10 million to $50 million to borrowers principally located in North America. It structures its investments as first lien senior secured loans, second lien senior secured loans, senior secured notes, senior subordinated notes, unitranche loans, and seeks warrants or other equity participation. The fund may take a board seat on its investee companies and exits its investments between three years and seven years.

Advisors' Opinion:

• [By Nathan Slaughter]

  All of this is to say that while I strive to hunt down and recommend attractive securities with double-digit yields -- and own a few, like Medley Capital Corp. (NYSE: MCC) -- they are the exception in this environment, not the rule.

Top 10 Income Companies To Buy Right Now: Kona Grill Inc.(KONA)

Kona Grill, Inc. owns and operates upscale casual dining restaurants in the United States. The company operates its restaurants under the Kona Grill name. As of September 22, 2011, it owned and operated 23 upscale casual restaurants in 16 states, including Arizona, Missouri, Nevada, Colorado, Nebraska, Indiana, Texas, Illinois, Michigan, Connecticut, Louisiana, Florida, Virginia, New Jersey, Minnesota, and Maryland. Kona Grill, Inc. was founded in 1994 and is based in Scottsdale, Arizona.

Advisors' Opinion:

• [By Quoth the Raven]

  My argument here is very similar to my argument I recently made with Kona Grill (KONA). Not only is NGS similar to Kona in the fact that they both have insiders with a huge stake in the game, but they both have the same growth prospects.

• [By Jon C. Ogg]

  The 24/7 Wall St. list of public companies expected to double sales in the next few years includes the following: Kona Grill Inc. (NASDAQ: KONA), LinkedIn Corp. (NYSE: LNKD),�Noodles & Co. (NASDAQ: NDLS),�Onyx Pharmaceuticals Inc. (NASDAQ: ONXX),�Michael Kors Holdings Ltd. (NYSE: KORS),�Questcor Pharmaceuticals Inc. (NASDAQ: QCOR),�Tesla Motors Inc. (NASDAQ: TSLA),�Under Armour Inc. (NYSE: UA),�Workday Inc. (NYSE: WDAY) and Yelp Inc.�(NYSE: YELP). Facebook Inc. (NASDAQ: FB)�might as well be considered a runner-up here, but it was a direct competitor of LinkedIn in the selections.

• [By Lisa Levin]

  Kona Grill (NASDAQ: KONA) shares rose 2.76% to reach a new 52-week high of $14.95. Kona Grill shares have jumped 66.10% over the past 52 weeks, while the S&P 500 index has gained 26.62% in the same period.